Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bellus Health Inc. - a GSK company
The primary objective of this study is to determine the therapeutic dose of BLU-5937 in patients with refractory chronic cough by assessing the change from baseline to week 4 in the 24-hour cough frequency with BLU-5937 relative to placebo.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Capable of giving signed informed consent
Refractory chronic cough (including unexplained chronic cough) for at least one year
Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose
You may not be if
Current smoker/vaper (all forms of smoking and inhaled substances, including , cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma
Respiratory tract infection within 4 weeks before screening
Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
History of malignancy in the last 5 years
History of alcohol or drug abuse within the last 3 years
Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
Previous participation in a BLU-5937 trial
Clareo Health | Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
